Embracing chimeric antigen receptors for relapsed chronic lymphocytic leukaemia
- PMID: 37597880
- DOI: 10.1016/S0140-6736(23)01611-2
Embracing chimeric antigen receptors for relapsed chronic lymphocytic leukaemia
Conflict of interest statement
MK declares research support or funding from Novartis; consultancy work for Abbvie, AstraZeneca, Celgene/Bristol-Myers Squibb, Adaptive Biotechnologies, ADC Therapeutics, Beigene, Genentech, Syncopation, and Caribou Biosciences; fees for speakers bureau from SeaGen; and participation on a data monitoring committee for Celgene and Genentech.
Comment on
-
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.Lancet. 2023 Aug 19;402(10402):641-654. doi: 10.1016/S0140-6736(23)01052-8. Epub 2023 Jun 6. Lancet. 2023. PMID: 37295445 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
